ZVRA / Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics com more_horizontal

Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs more_horizontal

Zevra's acquisition of Acer Therapeutics adds significant value to its rare disease-focused strategy. Acer's newly launched product, Olpruva, aligns w more_horizontal

The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after met more_horizontal

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to l more_horizontal

CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare more_horizontal

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner - Vice President more_horizontal

CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPhar more_horizontal